Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Occlusion of the healthy eye is the mainstay of amblyopia treatment. Occlusion therapy has practical limitations; many children actively resist treatment and some parents are marginally compliant with instructions.1 Even when parents are knowledgeable about amblyopia and patching, 22% report poor compliance.2 Strategies such as atropine, hand socks, inflatable water wings, benzoin tincture, occluder contact lenses, occlusive dressings, and sewing the patch to the brow and cheeks of noncompliant children have been used to improve compliance with patching.3
We conducted a pilot study of cyanoacrylate glue applied to a patch to increase its adhesiveness so that the child could not easily remove it. We used Dermabond Glue (Ethicon Inc, Johnson & Johnson Company, Sommerville, New Jersey) and Opticlude Junior patches (3M Company, St Paul, Minnesota). Before applying the patches to humans, their safety and adhesiveness was assessed by gluing them to the surface of fresh vegetables kept at room temperature for 1 week to see if there were any adverse chemical reactions between the glues and patch and between the glued patch and the vegetable surface. We observed no adverse effects. The glued patches were then applied to the upper arm of 4 adult volunteers (including the authors) for 1 week. Only one woman developed mild erythema, which resolved without treatment.
After approval by the research ethics board at The Hospital for Sick Children, Toronto, Canada, we recruited 5 children with monocular amblyopia due to strabismus, anisometropia, aphakia, and/or corneal opacity in whom all attempts of occlusion therapy had failed. Case details and patching are summarized in Table 1 and Table 2. Best corrected visual acuity was measured in both eyes and a complete eye examination was performed at the start of the study. Informed consent was obtained.
The glue was applied to the adhesive part of the patch. The patch was then applied over the good eye of the child before the glue dried. The children were allowed to go about their daily activities, including bathing and washing their faces. They wore the patch for 1 week. If any of the children wore the patch for less time, either because the patch spontaneously peeled off or was peeled off by the child, the time in hours was recorded. After 1 week, the glued patch was removed in the clinic quite easily and with little pain, as the patch was often partially detached by that time. We applied a fresh patch to the children after visual acuity testing in both eyes and external eye examination. The procedure was repeated for 4 consecutive weeks. With the use of glued patches, compliance improved gradually in all cases. Patient 3 wore the patch for 2 hours on 4 consecutive days at the end of the study. Patient 5 wore the patch for 6 days in the first week of the study and 7 days in the second week. Although our study was not designed to evaluate efficacy of amblyopia treatment using glued patches, improvement in visual acuity was noted in 2 cases. Three children developed mild erythema where the skin was in contact with the glue. In all these cases, the erythema resolved without any treatment in less than 2 days. None of the children developed excoriation or abrasion of the skin where the patch was applied.
Occlusion therapy is difficult and tedious for parents. Most studies report that at least one-third of families are unable to comply with treatment.4 Children aged 1 to 3 years may peel off their patches. With the exception of visual compromise brought on by using only the amblyopic eye, glued patches do not restrict the activity of the child in any way, like mittens or elbow restraints can.5 Occlusive black contact lenses put the healthy eye at some risk for infection or abrasion. There is no potential physical risk to the healthy eye with glued patches provided that care is taken to avoid allowing the glue to contact the ocular surface or eyelids. Should any problem arise with the use of cyanoacrylate-glued patches, including intolerance by the child or family, it can be easily removed with the help of white petroleum jelly. We recommend that the eyelids be closed before affixing the glued patch.
This was a pilot study with a small sample size to investigate the potential use of a novel method of increasing patching compliance. To better understand the efficacy, risks, and suitability of glued patches, we recommend studies with larger numbers of patients and various types of amblyopia.
Correspondence: Dr Levin, Department of Ophthalmology, M158, Hospital for Sick Children, 555 University Ave, Toronto, ON M5G 1X8, Canada (alex.levin@sickkids.ca).
Author Contributions: Dr Levin had full access to the original data and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: This study was supported in part by Brandan's Eye Research Fund.
Previous Presentations: This study was presented in part at the 45th Annual Research Day, Department of Ophthalmology, University of Toronto, May 23, 2003, and at the 1st International Pediatric Ophthalmology & Strabismus Conference, Al-Shifa Trust Eye Hospital; December 10, 2005; Rawalpindi, Pakistan.
Additional Contributions: J. Raymond Buncic, MD, FRCSC, referred 1 patient and David Smith, MD, FRCSC, referred 2.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Archives of Ophthalmology editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.